GlassScriptPhysician profile
Surekha Boddipalli
NPI 1255656948
$3,533.96
in general payments reported to CMS, 2019-2025
46 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.05 · 2020: $178 · 2021: $347 · 2022: $1,138 · 2023: $1,605 · 2024: $28.63 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,794.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $290.23 | 2022-2023 | Verzenio |
| Genentech USA, INC. | $272.71 | 2019-2023 | Kadcyla, Perjeta, Phesgo |
| Seagen INC. | $210.19 | 2019-2023 | Padcev, Adcetris, Tivdak |
| Janssen Biotech, INC. | $198.21 | 2020-2023 | Darzalex, Tecvayli |
| Novartis Pharmaceuticals Corporation | $187.40 | 2021-2023 | Piqray, Kisqali |
| Merck Sharp & Dohme LLC | $181.28 | 2022-2023 | Keytruda, Lynparza |
| Amgen INC. | $172.45 | 2019-2023 | Kyprolis, Blincyto |
| Regeneron Healthcare Solutions, INC. | $128.86 | 2022-2023 | Libtayo |
| Astellas Pharma US INC | $117.11 | 2022-2023 | Xospata, Padcev, Xtandi |
| Celgene Corporation | $115.83 | 2022-2023 | Pomalyst, Reblozyl |
| Emd Serono, INC. | $114.32 | 2021-2025 | Tepmetko |
| E.R. Squibb & Sons, L.L.C. | $109.40 | 2022-2023 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $108.70 | 2021-2025 | Enhertu |
| Glaxosmithkline, LLC. | $102.75 | 2022-2023 | Zejula, Jemperli |
| Astrazeneca Pharmaceuticals LP | $85.28 | 2022-2025 | Imfinzi, Lynparza |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surekha Boddipalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.